Human Microbiome Manufacturing Services worth $0.27 million by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., Dec. 17, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the Human Microbiome Manufacturing Services Market  is projected to grow from about USD 0.11 billion in 2025 to USD 0.27 billion by 2031, at a CAGR of 16.7%.

Browse 250 market data Tables and 50 Figures spread through 414 Pages and in-depth TOC on " Human Microbiome Manufacturing Services Market - Global Forecast to 2031"

Human Microbiome Manufacturing Services Market Size & Forecast:

• Market Size Available for Years: 2023–2031
• 2025 Market Size: USD 0.11 billion
• 2031 Projected Market Size: USD 0.27 billion
• CAGR (2025–2030): 16.7%

Human Microbiome Manufacturing Services Market Trends & Insights:

• By type, the fermentation & downstream processing segment is expected to register the highest CAGR of 16.8% due to the central role of these processes in producing high-quality, scalable, and GMP-compliant live biotherapeutic products.
• By disease, the gastrointestinal disease segment accounted for the largest share of the human microbiome manufacturing services market in 2024 due to the concentration of clinical programs targeting gut-related conditions.
• North America accounted for the largest share of the human microbiome manufacturing services market in 2024 due to the strong concentration of advanced CDMOs and robust biopharmaceutical activity.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255565161 

These market players have implemented various strategies, including product launches, acquisitions, agreements, collaborations, and expansions, to strengthen their market positions. In September 2024, Lonza expanded its microbial manufacturing capacity in Germany, scaling up its ability to produce live biotherapeutic products (LBPs). This expansion enhances Lonza's ability to meet the rising demand for clinical- and commercial-scale microbiome and biologics manufacturing.

By type, the fermentation & downstream processing segment accounted for the largest share of the market in 2024.

the human microbiome manufacturing services market is divided into strain development & optimization, fermentation & downstream processing, formulation & fill/finish, and other services. In 2024, fermentation & downstream processing accounted for the largest share. This segment encompasses large-scale microbial cultivation, anaerobic processing, purification, and stabilization, all of which are necessary for the production of live biotherapeutics and microbial consortia. Growth is driven by increasing clinical and commercial demand for GMP-compliant microbial products and the complexity of anaerobic strains. Advanced bioprocessing technologies, scalable systems, and robust purification methods ensure consistent quality, making this segment crucial for the development of complete microbiome products.

Request Sample Pages@https://www.marketsandmarkets.com/requestsampleNew.asp?id=255565161

By end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market in 2024.

End users segment the human microbiome manufacturing services market into pharmaceutical & biotechnology companies, academic & research institutes, and other users. In 2024, pharmaceutical & biotechnology firms held the largest share. They lead the development of microbiome-based therapies, including live biotherapeutics, microbial consortia, and next-generation probiotics. These firms depend on specialized CDMOs for strain development, fermentation, downstream processing, formulation, and fill/finish under GMP conditions. Increasing clinical programs, chronic microbiome-related disorders, substantial investments, and collaborations with CDMOs drive their dominance, making them the most influential end users in the market.

North America accounted for the largest share of the market in 2024

In 2024, North America held the largest share of the human microbiome manufacturing services market. This growth is driven by a strong biotech ecosystem, advanced microbial processing, and a focus on live biotherapeutic products (LBPs). The US has made regulatory progress, including FDA approvals and fast-track designations, which boost investment in strain development, fermentation, downstream processing, and formulation. High clinical activity in metabolic, gastrointestinal, and immune disorders, along with specialized CDMOs offering GMP-compliant and anaerobic processing, supports market expansion. Strong funding, clear regulations, and global trial participation reinforce North America's leadership in microbiome sector manufacturing.

Inquire Before Buying@https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=255565161

Top Companies in Spare Parts Management (SPM) Market:

The Top Companies in Human Microbiome Manufacturing Services Market include Lonza (Switzerland), Evonik (Germany), Lallemand Inc. (Canada), Cerbios-Pharma SA (Canada), Eurofins Scientific (Luxembourg), and Charles River Laboratories (US), among others.

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

Related Reports:

Clinical Microbiology Market - Global Forecast to 2030

High Throughput Screening Market - Global Forecast to 2029

Gastrointestinal Products Market - Global Forecast to 2029      

Infectious Disease Diagnostics Market - Global Forecast to 2030

Human Microbiome Market - Global Forecast to 2031

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/human-microbiome-manufacturing-services-worth-0-27-million-by-2031--marketsandmarkets-302644480.html

SOURCE MarketsandMarkets